Viridian Therapeutics, Inc. (LON:0K1R)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.29B +55.5% |
| Revenue (ttm) | 53.71M +23,382.8% |
| Net Income | -229.67M |
| EPS | -2.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375 |
| Average Volume | 8,052 |
| Open | 17.07 |
| Previous Close | 16.78 |
| Day's Range | 16.29 - 17.14 |
| 52-Week Range | 12.16 - 34.31 |
| Beta | 0.82 |
| RSI | 50.85 |
| Earnings Date | Aug 7, 2026 |
About Viridian Therapeutics
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o... [Read more]
Financial Performance
In 2025, Viridian Therapeutics's revenue was $70.85 million, an increase of 23359.93% compared to the previous year's $302,000. Losses were -$281.93 million, 35.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
Stifel lowered the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $48 and keeps a Buy rating on the shares. The firm has modeled a slower franchise ramp…
Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
The deal size was increased to $125M in common stock from $100M in common stock. Jefferies, Leerink and Goldman Sachs acted as joint book running managers for the offering. Published…
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $30 and keeps an Outperform rating on the shares after its Q1 results. On ele’, RBC…
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoim...
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoim...
Viridian Therapeutics Transcript: Study result
REVEAL-2, the largest pivotal trial in chronic TED, showed Ellay met all primary and key secondary endpoints with strong efficacy and a favorable safety profile. Both Q4 and Q8 dosing regimens offer IV-like results in a convenient auto-injector, supporting plans for regulatory submission and broad market expansion.
Viridian announces REVEAL-2 phase 3 study met primary endpoint
Viridian Therapeutics (VRDN) announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease, TED. Elegrobart is a subcutaneously de...
Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)
Reports Q1 revenue $141k, consensus $27.75k. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline...
Viridian eye disease drug benefits chronic patients in late-stage trial
Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics price target lowered to $33 from $36 at Truist
Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $33 from $36 and keeps a Buy rating on the shares. The firm is adjusting its model with refreshed…
Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI
Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $24 from $32 and keeps an Outperform rating on the shares in conjunction with a Q1 earnings preview.
Viridian Therapeutics price target lowered to $36 from $40 at Truist
Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing…
Viridian Therapeutics price target lowered to $31 from $37 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Viridian Therapeutics (VRDN) to $31 from $37 and keeps an Outperform rating on the shares. The firm says it has…
Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital
RBC Capital lowered the firm’s price target on Viridian Therapeutics (VRDN) to $30 from $42 and keeps an Outperform rating on the shares. Amgen’s (AMGN) Tepezza-OBI showed better numerical results…
Viridian Therapeutics removed from Best Ideas List at Wedbush
Wedbush is removing Vridian Therapeutics from the Best Ideas List due to the firm’s investment price discipline. Wedbush has an Outperform rating on the shares with a price target of…
Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’
Leerink analyst Thomas Smith notes Viridian Therapeutics’ (VRDN) shares are under pressure following topline results from Amgen’s (AMGN) Phase 3 trial of SC Tepezza utilizing an on-body injector for t...
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.
Viridian sinks after Amgen thyroid eye disease study hits endpoints
Shares of Viridian Therapeutics (VRDN) are moving lower after Amgen’s (AMGN) Phase 3 trial of Tepezza administered by subcutaneous injection via an on-body injector in participants with moderate-to-se...
Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list
Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $32 from $45 and keeps an Outperform rating on the shares, which the analyst also removed from the…
Viridian Therapeutics price target lowered to $37 from $44 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Viridian Therapeutics (VRDN) to $37 from $44 and keeps an Outperform rating on the shares. Simply put, the REVEAL-1 study…
Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $20 from $29 and keeps an Equal Weight rating on the shares. While the move on Monday may…
Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $41 and keeps a Buy rating on the shares. Viridian Therapeutics announced that elegrobart met the…
Viridian Therapeutics Transcript: Study result
REVEAL-1 phase III trial in active thyroid eye disease met its primary endpoint, with both Q4 and Q8 weekly subcutaneous regimens of ele showing robust, rapid, and clinically meaningful proptosis and diplopia responses, and a favorable safety profile. Home administration in as few as three doses could expand the $2B TED market.